Seeking Alpha

Takeda Pharmaceutical Co., Ltd. ADR (TKPYY)

- OTCPK - Current
  • Mar. 19, 2013, 8:18 AM
    NPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR)
    | Mar. 19, 2013, 8:18 AM | Comment!
  • Jul. 2, 2012, 2:38 PM
    Piper Jaffray looks at other potential takeout candidates in the biotech space post-Amylin, highlighting BioMarin (BMRN +3.8%), Affymax (AFFY +1%), Theravance (THRX +8.3%), and Rigel Pharmaceuticals (RIGL +2.3%) all as potential candidates. Piper notes that BioMarin could fetch as much as $79 per share, and notes that Japanese drug heavyweight Takeda Pharmaceuticals (TKPYY.PK) could be the most likely suitor for Affymax.
    | Jul. 2, 2012, 2:38 PM | Comment!
  • Apr. 11, 2012, 7:25 AM
    Takeda Pharmaceutical (TKPYY.PK) buys privately-held URL Pharma for $800M in a deal that could include performance payments down the road. URL's major product is gout treatment Colcrys.
    | Apr. 11, 2012, 7:25 AM | Comment!
  • Mar. 28, 2012, 3:09 PM
    Amylin (AMLN +48.6%) investors cheer the rumor it rejected a $3.5B offer from Bristol-Myers Squibb, and analysts expect higher bids. Deutsche Bank says AMLN could be worth up to $31/share given an "acquirer with diabetes sales force can cut SG&A by 80% and R&D by 40%." Piper Jaffray names BMY, MRK and TKPYY.PK as potential sutiors; Leerink Swann suggests AZN.
    | Mar. 28, 2012, 3:09 PM | Comment!
TKPYY vs. ETF Alternatives
Company Description
Research & Development, Manufacturing, Sales and Marketing, and Import/Export of Pharmaceutical Drugs, etc.
Sector: Healthcare
Country: Japan